Take care of the health of the nation by maximizing the provision of operators of the pharmaceutical market of Ukraine and medical facilities with a wide range of guaranteed quality medicines and related products. Create comfortable co-operation conditions for each client, with an individual approach and maximum satisfaction of needs
BaDM has become an industry leader relying on highly professional employees and reliable business partners
BaDM – 25 years of dynamic development and constant perfection in line with the high international standards
BaDM is a repeated winner of all-Ukrainian contest “Panacea” in nominations of “Distributor of the year” and “Company of the year”
Allergy is one of the most widespread pathologies in the world. Allergic rhinitis and urticaria are among the most common allergic diseases. Thus, 20-40% of the world's population suffers from allergic rhinitis.At least once in a lifetime every fifth person had suffered from urticarial.
In almost every country in the world, there is a trend towards ageing of the population so the senile asthenia is growing more urgent. The researchers from the United States has detected that the use of analgesics and soporific provokes this condition. The scientists from the Florida Atlantic University have found that taking of both sleeping pills and pain medication in older age may lead to the development of senile asthenia syndrome (SAS). The risk for SAS development increases if patients took both classes of drugs concurrently.
Inclisiran by the Medicines Company, USA demonstrated an excellent safety profile and caused the competitors represented by Regeneron and Amgen some anxiety. The Medicines Company announced new results from a Phase 3 clinical trial of Inclisiran to reduce the low-density lipoprotein cholesterol (LDL “bad” cholesterol).The drug was evaluated in the patient population (1 561 participants) with atherosclerotic vascular disease and elevated LDL-C. The MedCo proved that the safety profile of Iinclisiran was similar with placebo.
The global seasonal influenza vaccine market could reach $ 6.5 bn. by 2028. At the end of 2018, the seasonal influenza vaccine across the eight major markets was estimated at $ 4.6 billion. According to GlobalData, the analytical company, moderate growth is expected over the next 10 years on average by 3.7% annually, and by the end of 2028, this market could increase to $ 6.5 billion.
A new drug to treat Alzheimer’s disease developed by China scientists has been approved by China National Medical Products Administration. GV-971(Oligomannate), a seaweed-based drug, has been jointly developed by the Ocean University of China, the Shanghai Institute of Materia Medica under the Chinese Academy of Sciences and Green Valley Pharmaceutical Company Ltd.
Manufacturers and suppliers of vital medicines and medical products say that the British authorities have not explained yet how their orders will be processed if the UK leaves the European Union at the end of October.
A study run by the marketers showed that the influence of the pharmacist on a buyer’s choice of medicine greatly depends on what kind of medicine the buyer came to the pharmacy to buy.
Does the buyer have a doctor’s prescription, is the product intended for use in intimate places, how familiar the buyer is with the pharmacist and to what extent the buyer can trust one or another pharmacist, etc.
According to the survey conducted by the consulting firm Decision, the physicians in the USA are willing to devote less time communicating with medical representatives.
Based on the survey, more than half from 1285 of the responded physicians, simply don’t have time to meet up with medical representatives.
Polycystic kidney disease (PKD) is a genetic condition affecting about 12 million people worldwide.
Polycystic kidney disease is currently incurable; end-stage kidney failure requires treatment with dialysis or a kidney transplantation to prolong the life of PKD patients. But such methods are not available to everyone.
